for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Achillion Pharmaceuticals, Inc.

ACHN.O

Latest Trade

6.21USD

Change

0.02(+0.32%)

Volume

1,584,429

Today's Range

6.18

 - 

6.22

52 Week Range

1.29

 - 

6.46

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.19
Open
6.21
Volume
1,584,429
3M AVG Volume
65.49
Today's High
6.22
Today's Low
6.18
52 Week High
6.46
52 Week Low
1.29
Shares Out (MIL)
140.05
Market Cap (MIL)
866.89
Forward P/E
-10.15
Dividend (Yield %)
--

Next Event

Achillion Pharmaceuticals Inc Extraordinary Shareholders Meeting

Latest Developments

More

Achillion Announces Clearance Of Investigational New Drug Application For ACH-5228

Achillion - Cash, Cash Equivalents And Marketable Securities As Of Sept. 30, 2019 Was $229 Mln

Alexion Pharmaceuticals Says If Merger With Achillion Terminated Under Certain Circumstances, Achillion May Be Required To Pay Co Fee Equal To $20 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Industry

Major Drugs

Contact Info

300 George St

+1.203.6247000

http://www.achillion.com/

Executive Leadership

Nicole Vitullo

Independent Chairman of the Board

Joseph Truitt

President, Chief Executive Officer, Director

Brian Di Donato

Chief Financial Officer, Senior Vice President

Paul F. Firuta

Chief Operating Officer, Executive Vice President

Martha E. Manning

Executive Vice President, General Counsel, Corporate Secretary

Key Stats

3.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.450

2017

-0.620

2018

-0.510

2019(E)

-0.585
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.99
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-29.87
Return on Equity (TTM)
-28.38

Latest News

Latest News

Alexion fortifies rare blood disorder drugs business with Achillion deal

Alexion Pharmaceuticals Inc <ALXN.O> on Wednesday agreed to buy smaller biotech Achillion Pharmaceuticals Inc <ACHN.O> in a deal initially valued at $930 million, as the company looks to retain its leadership in treating certain rare blood disorders.

Drugmaker Alexion to buy biotech Achillion in $930 mln deal

Alexion Pharmaceuticals Inc on Wednesday agreed to buy small biotech Achillion Pharmaceuticals Inc in a $930 million deal, to boost its pipeline of rare disease treatments.

BRIEF-Achillion Pharma Says Truitt Gets Annualized Base Salary Of $560,000

* ACHILLION PHARMACEUTICALS SAYS JOSEPH TRUITT RECEIVES ANNUALIZED BASE SALARY OF $560,000, IN CONNECTION WITH APPOINTMENT AS CEO - SEC FILING

BRIEF-Achillion Reports Q1 Loss Per Share $0.15

* ACHILLION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND MANAGEMENT TRANSITION

BRIEF-Achillion Announces ACH-4471 Receives Positive Opinion For Orphan Drug Status In EU For The Treatment Of C3 Glomerulopathy

* ACHILLION ANNOUNCES ACH-4471 RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR THE TREATMENT OF C3 GLOMERULOPATHY

BRIEF-Achillion Forecasts 2018 Loss Of $0.55-$0.58 Per Share

* ACHILLION ANNOUNCES RESTRUCTURING TO ADVANCE CORPORATE STRATEGY; ANNOUNCES 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-Achillion Initiates Phase I First-In Study Of ACH-5228

* ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D

BRIEF-Achillion Announces ACH-4471 Granted Orphan Drug Designation For The Treatment Of C3 Glomerulopathy

* ACHILLION ANNOUNCES ACH-4471 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF C3 GLOMERULOPATHY (C3G) AND THE INITIATION OF A PHASE 1 EXTENDED-RELEASE BIOAVAILABILITY STUDY

BRIEF-Achillion announces pricing of secondary offering of common stock

* Achillion announces pricing of secondary offering of common stock

BRIEF-Achillion announces proposed secondary offering of common stock

* Achillion announces proposed secondary offering of common stock

BRIEF-Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

* Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

BRIEF-Achillion says ACH-4471 granted orphan drug designation by FDA

* Achillion announces ACH-4471 granted orphan drug designation by the FDA and positive opinion for orphan drug designation in the european union for the treatment of paroxysmal nocturnal hemoglobinuria

BRIEF-Achillion Q3 loss per share $0.14

* Achillion reports third quarter 2017 financial results and provides update on clinical programs

BRIEF-RTW Investments reports 5.2 pct passive stake in Achillion Pharmaceuticals - SEC filing

* RTW Investments LP reports 5.2 percent passive stake in Achillion Pharmaceuticals Inc as of September 18, 2017 - SEC filing Source text: (http://bit.ly/2wXrbF8) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Achillion announces termination of worldwide collaboration for hepatitis c with Janssen

* Achillion announces termination of worldwide collaboration for hepatitis c with Janssen Further company coverage:

BRIEF-Achillion Pharmaceuticals says Joel Barrish plans to leave co

* Achillion Pharmaceuticals Inc - announced that Joel Barrish, executive vice president and chief scientific officer, plans to leave company

BRIEF-Achillion Q1 loss per share $0.15

* Achillion reports first quarter 2017 financial results and provides update on clinical programs

BRIEF-Achillion announces initiation of patient dosing in phase 2 study of ACH-4471

* Achillion announces initiation of patient dosing in phase 2 study of ACH-4471 for paroxysmal nocturnal hemoglobinuria

BRIEF-Achillion Pharmaceuticals to support a natural history study of C3 glomerulopathy

* Achillion Pharmaceuticals to support a natural history study of C3 glomerulopathy, a rare renal disorder, conducted by experts at Imperial College London Source text for Eikon: Further company coverage:

BRIEF-Achillion Pharmaceuticals Inc says files for mixed shelf of upto $250 million

* Achillion Pharmaceuticals Inc says files for mixed shelf of upto $250 million - SEC filing Source text for Eikon: (http://bit.ly/2l58Pa8) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up